Hyperemesis gravidarum therapy options widen past doxylamine-pyridoxine
Doxylamine-pyridoxine and ondansetron maturity, structured outpatient infusion pathways, and emerging GDF15-targeted programs are reshaping hyperemesis gravidarum management.
Hyperemesis gravidarum (severe nausea and vomiting in pregnancy) has been a doxylamine-pyridoxine and ondansetron category with hospitalisation for severe cases. Structured outpatient hydration and antiemetic infusion pathways are formalising, GDF15 has emerged as a major mechanistic driver and emerging GDF15-targeted programs are entering early clinical trials, and integrated obstetric-and-mental-health care models are emerging. The maternal-fetal medicine integration is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.